

Amniotics granted key U.S. patent for PulmoStem™

Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the US Patent and Trademark Office (USPTO) has approved a patent application for the company's stem cell product PulmoStem™. This newly allowed U.S. patent, with application no. 17/646539, "Use of term amniotic fluid cells for the treatment of acute and chronic respiratory disease", provides Amniotics with exclusive commercial rights in the U.S. at least until 2040 for the use of the amniotic derived stem cell product PulmoStem™ in the treatment of Acute Respiratory Distress Syndrome (ARDS).

Amniotics stem cell product PulmoStem™ is expected to be efficacious in various acute and chronic diseases of the lung through modulation of the immune response and anti-fibrotic capabilities. The first clinical study to commence this summer is targeting hospitalized patients suffering from respiratory tract infections due to COVID-19 and other causes, which can cause ARDS.

"This is the first U.S. patent granted in Amniotics patent portfolio and it confirms that our stem cell products and production methods are patentable, novel, and innovative. This approval also validates our long-term IP strategy, matching high quality patent applications with Amniotics products, ensuring market exclusivity for Amniotics technology. This is a great milestone, reached via a team effort, and I want to take the opportunity to thank our founders, inventors, and external consultants including our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens", says Kåre Engkilde, CEO at Amniotics

For more information please contact

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com

or

Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

Attachments

[Amniotics granted key U.S. patent for PulmoStem™](#)